230 related articles for article (PubMed ID: 16777274)
1. Cross-reactivity of influenza A (H3N2) hemagglutination-inhibition antibodies induced by an inactivated influenza vaccine.
Kojimahara N; Maeda A; Kase T; Yamaguchi N
Vaccine; 2006 Aug; 24(33-34):5966-9. PubMed ID: 16777274
[TBL] [Abstract][Full Text] [Related]
2. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine.
Del Giudice G; Hilbert AK; Bugarini R; Minutello A; Popova O; Toneatto D; Schoendorf I; Borkowski A; Rappuoli R; Podda A
Vaccine; 2006 Apr; 24(16):3063-5. PubMed ID: 16464520
[TBL] [Abstract][Full Text] [Related]
3. Cross-protection against homologous drift variants of influenza A and B after vaccination with split vaccine.
Heckler R; Baillot A; Engelmann H; Neumeier E; Windorfer A
Intervirology; 2007; 50(1):58-62. PubMed ID: 17164559
[TBL] [Abstract][Full Text] [Related]
4. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.
Ansaldi F; Bacilieri S; Durando P; Sticchi L; Valle L; Montomoli E; Icardi G; Gasparini R; Crovari P
Vaccine; 2008 Mar; 26(12):1525-9. PubMed ID: 18294741
[TBL] [Abstract][Full Text] [Related]
5. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
[TBL] [Abstract][Full Text] [Related]
6. Mismatch between the 1997/1998 influenza vaccine and the major epidemic A(H3N2) virus strain as the cause of an inadequate vaccine-induced antibody response to this strain in the elderly.
de Jong JC; Beyer WE; Palache AM; Rimmelzwaan GF; Osterhaus AD
J Med Virol; 2000 May; 61(1):94-9. PubMed ID: 10745239
[TBL] [Abstract][Full Text] [Related]
7. Cross-reactive and vaccine-induced antibody to an emerging swine-origin variant of influenza A virus subtype H3N2 (H3N2v).
Skowronski DM; Janjua NZ; De Serres G; Purych D; Gilca V; Scheifele DW; Dionne M; Sabaiduc S; Gardy JL; Li G; Bastien N; Petric M; Boivin G; Li Y
J Infect Dis; 2012 Dec; 206(12):1852-61. PubMed ID: 22872731
[TBL] [Abstract][Full Text] [Related]
8. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
Ansaldi F; Canepa P; Ceravolo A; Valle L; de Florentiis D; Oomen R; Vogel FR; Denis M; Samson SI; Icardi G
Vaccine; 2012 Apr; 30(18):2908-13. PubMed ID: 22342501
[TBL] [Abstract][Full Text] [Related]
9. Humoral and cellular immune responses in children given annual immunization with trivalent inactivated influenza vaccine.
Zeman AM; Holmes TH; Stamatis S; Tu W; He XS; Bouvier N; Kemble G; Greenberg HB; Lewis DB; Arvin AM; Dekker CL
Pediatr Infect Dis J; 2007 Feb; 26(2):107-15. PubMed ID: 17259871
[TBL] [Abstract][Full Text] [Related]
10. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma.
Zuccotti G; Amendola A; Viganò A; Pariani E; Zappa A; Pogliani L; Giacomet V; Savarino A; Podestà A; Rottoli A; Tanzi E; Zanetti A; Radaelli G
Vaccine; 2007 Sep; 25(37-38):6692-8. PubMed ID: 17697730
[TBL] [Abstract][Full Text] [Related]
11. Vaccination-induced HI antibody response to intraepidemic influenza A(H3N2) virus variants of the 1996-1997 epidemic season.
Pyhälä R; Ikonen N; Santanen R; Haanpää M; Visakorpi R; Jäppinen P; Valle M
J Med Virol; 2001 Nov; 65(3):584-9. PubMed ID: 11596097
[TBL] [Abstract][Full Text] [Related]
12. An influenza A/H3 outbreak during the 2004/2005 winter in elderly vaccinated people living in a nursing home.
Iorio AM; Neri M; Lepri E; Camilloni B; Basileo M; Sigismondi N; Fabiani C; Calzoletti L; Puzelli S; Donatelli I
Vaccine; 2006 Nov; 24(44-46):6615-9. PubMed ID: 16828941
[TBL] [Abstract][Full Text] [Related]
13. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
[TBL] [Abstract][Full Text] [Related]
14. Lack of effect of a booster dose of influenza vaccine in hemodialysis patients.
Tanzi E; Amendola A; Pariani E; Zappa A; Colzani D; Logias F; Perego A; Zanetti AR
J Med Virol; 2007 Aug; 79(8):1176-9. PubMed ID: 17596830
[TBL] [Abstract][Full Text] [Related]
15. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
[TBL] [Abstract][Full Text] [Related]
16. [Cross immunity study of two different influenza A3 virus vaccine strain].
Zhang ZL; Zhu XJ; Zhang Y
Zhonghua Yu Fang Yi Xue Za Zhi; 2010 Jun; 44(6):522-5. PubMed ID: 21055127
[TBL] [Abstract][Full Text] [Related]
17. Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007.
Skowronski DM; De Serres G; Dickinson J; Petric M; Mak A; Fonseca K; Kwindt TL; Chan T; Bastien N; Charest H; Li Y
J Infect Dis; 2009 Jan; 199(2):168-79. PubMed ID: 19086914
[TBL] [Abstract][Full Text] [Related]
18. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
Camilloni B; Neri M; Lepri E; Iorio AM
Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623
[TBL] [Abstract][Full Text] [Related]
19. Immune response to influenza vaccination in community-dwelling Chinese elderly persons.
Hui SL; Chu LW; Peiris JS; Chan KH; Chu D; Tsui W
Vaccine; 2006 Jun; 24(25):5371-80. PubMed ID: 16713661
[TBL] [Abstract][Full Text] [Related]
20. Antibodies cross-reactive to influenza A (H3N2) variant virus and impact of 2010-11 seasonal influenza vaccine on cross-reactive antibodies - United States.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2012 Apr; 61(14):237-41. PubMed ID: 22495226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
